Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)

The PerVision trial utilizes an approach of a patient-individual cancer vaccine with sarcoma-specific peptides in metastasized fusion-driven sarcoma patients determined by next generation whole exome sequencing of tumor and normal tissue as well as RNA sequencing of the tumor. This approach is applicable to all patients independent of the expression of distinct tumor associated antigens, and independent of their human leukocyte antigen-typing (HLA-typing). The results of this study can directly be translated to other tumor entities. It is an interventional, multicenter, open-label, phase I/I

Trial Details

NCT ID
NCT06094101
Phase
PHASE1 / PHASE2
Sponsor
University Hospital Tuebingen
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Peptide vaccine IPX
Locations (sample)
  • Essen, Germany|51.45657,7.01228
  • Frankfurt am Main, Germany|50.11552,8.68417
  • Freiburg im Breisgau, Germany|47.9959,7.85222
  • Tübingen, Germany|48.52266,9.05222

Key Eligibility Criteria

  • Screening Stage 1:
  • Confirmed metastatic fusion-driven rhabdomyosarcoma, Ewing- and synovial sarcoma in first or second complete remission (CR) or partial response (PR…
  • Whole exome sequencing and RNA sequencing data of the gene fusion (fusion-breakpoint RNA sequence) must be available by registration to the INFORM …
  • Screening stage 2:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →